CA2869474C - Methods and compositions for increasing red blood cells - Google Patents

Methods and compositions for increasing red blood cells Download PDF

Info

Publication number
CA2869474C
CA2869474C CA2869474A CA2869474A CA2869474C CA 2869474 C CA2869474 C CA 2869474C CA 2869474 A CA2869474 A CA 2869474A CA 2869474 A CA2869474 A CA 2869474A CA 2869474 C CA2869474 C CA 2869474C
Authority
CA
Canada
Prior art keywords
bmp9
polypeptide
composition
bmp10
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2869474A
Other languages
English (en)
French (fr)
Other versions
CA2869474A1 (en
Inventor
Ravindra Kumar
Naga Venkata Sai Rajasekhar Suragani
John Knopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA2869474A1 publication Critical patent/CA2869474A1/en
Application granted granted Critical
Publication of CA2869474C publication Critical patent/CA2869474C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2869474A 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells Active CA2869474C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621154P 2012-04-06 2012-04-06
US61/621,154 2012-04-06
PCT/US2013/035305 WO2013152213A1 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells

Publications (2)

Publication Number Publication Date
CA2869474A1 CA2869474A1 (en) 2013-10-10
CA2869474C true CA2869474C (en) 2021-08-03

Family

ID=49301055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2869474A Active CA2869474C (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells

Country Status (6)

Country Link
US (4) US9809636B2 (enExample)
EP (2) EP3351260B1 (enExample)
JP (4) JP6234993B2 (enExample)
AU (3) AU2013243388B2 (enExample)
CA (1) CA2869474C (enExample)
WO (1) WO2013152213A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
SI3286206T1 (sl) 2015-04-22 2021-07-30 Biogen Ma Inc. Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EP3370754B1 (en) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CN116531490A (zh) 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
KR100255415B1 (ko) 1991-06-25 2000-05-01 브루스 엠. 에이센 비엠피-9 조성물
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
WO1994020539A1 (en) 1993-03-04 1994-09-15 Creative Biomolecules, Inc. Method and compositions for recombinant osteogenic protein production
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
EP1863518A2 (en) 2005-03-30 2007-12-12 Wyeth Methods for stimulating hair growth by administering bmps
EP2781222B1 (en) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
WO2008076437A2 (en) 2006-12-18 2008-06-26 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
EP2265603B1 (en) * 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
KR20190128254A (ko) 2008-05-02 2019-11-15 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
EP2291401A2 (en) 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
KR20110031951A (ko) * 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
EP3290439B1 (en) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
CN102655872B (zh) 2009-08-13 2016-01-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
JP2012238811A (ja) 2011-05-13 2012-12-06 Toshiba Corp 半導体不揮発性記憶装置およびその製造方法
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN104411720B (zh) * 2012-07-02 2018-05-11 协和发酵麒麟株式会社 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
JP6976859B2 (ja) 2015-05-13 2021-12-08 セルジーン コーポレイション ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療

Also Published As

Publication number Publication date
JP2017190344A (ja) 2017-10-19
EP2844272A4 (en) 2015-11-04
AU2013243388A1 (en) 2014-10-23
JP2019156858A (ja) 2019-09-19
EP3351260B1 (en) 2022-07-13
US10344066B2 (en) 2019-07-09
US11807673B2 (en) 2023-11-07
WO2013152213A1 (en) 2013-10-10
US20130281371A1 (en) 2013-10-24
JP2021107453A (ja) 2021-07-29
US10829534B2 (en) 2020-11-10
AU2013243388B2 (en) 2018-01-25
AU2018202326A1 (en) 2018-04-26
JP2015514115A (ja) 2015-05-18
AU2021201196A1 (en) 2021-03-11
JP6234993B2 (ja) 2017-11-22
US20180186851A1 (en) 2018-07-05
US20200115428A1 (en) 2020-04-16
CA2869474A1 (en) 2013-10-10
AU2018202326B2 (en) 2020-11-26
US20210277082A1 (en) 2021-09-09
EP2844272A1 (en) 2015-03-11
US9809636B2 (en) 2017-11-07
EP3351260A1 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
US11807673B2 (en) Methods and compositions for increasing red blood cells
JP7329573B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
JP6860533B2 (ja) 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用
US11642394B2 (en) Methods and compositions using GDF15 polypeptides for increasing red blood cells
US20230234998A1 (en) Twisted gastrulation polypeptides and uses thereof
HK1245147A1 (zh) 激活素-actrii的拮抗劑及在提高紅細胞水平中的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180322

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251006

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251107